Apidra Related Published Studies
Well-designed clinical trials related to Apidra (Insulin Glulisine)
Effects of initiation and titration of a single pre-prandial dose of insulin glulisine while continuing titrated insulin glargine in type 2 diabetes: a 6-month 'proof-of-concept' study. [2011.11]
Insulin glulisine compared to insulin aspart and to insulin lispro administered by continuous subcutaneous insulin infusion in patients with type 1 diabetes: a randomized controlled trial. [2011.06]
Effects of insulin and oral anti-diabetic agents on glucose metabolism, vascular dysfunction and skeletal muscle inflammation in type 2 diabetic subjects. [2011.05]
A stepwise approach to insulin therapy in patients with type 2 diabetes mellitus and basal insulin treatment failure. [2011.05]
Comparable efficacy and safety of insulin glulisine and insulin lispro when given as part of a Basal-bolus insulin regimen in a 26-week trial in pediatric patients with type 1 diabetes. [2011.03]
Comparative pharmacodynamic and pharmacokinetic characteristics of subcutaneous insulin glulisine and insulin aspart prior to a standard meal in obese subjects with type 2 diabetes. [2011.03]
Randomized study of basal-bolus insulin therapy in the inpatient management of patients with type 2 diabetes undergoing general surgery (RABBIT 2 surgery). [2011.02]
Do different body colors and labels of insulin pens enhance a patient's ability to correctly identify pens for injecting long-acting versus short-acting insulins? [2011.01.01]
Glulisine versus human regular insulin in combination with glargine in noncritically ill hospitalized patients with type 2 diabetes: a randomized double-blind study. [2010.12]
Insulin glulisine has a faster onset of action compared with insulin aspart in healthy volunteers. [2010.10]
Bioequivalence between two human insulin analogs in Chinese population: Glulisine and Lispro. [2010.08]
Effects of insulin glulisine as mono- or add-on therapy in patients with type 2 diabetes mellitus. [2009.09]
Insulin analogs versus human insulin in the treatment of patients with diabetic ketoacidosis: a randomized controlled trial. [2009.07]
Effect of insulin glulisine on microvascular blood flow and endothelial function in the postprandial state. [2008.05]
A comparison of preprandial insulin glulisine versus insulin lispro in people with Type 2 diabetes over a 12-h period. [2008.02]
Randomized study of basal-bolus insulin therapy in the inpatient management of patients with type 2 diabetes (RABBIT 2 trial). [2007.09]
Safety of insulin glulisine when given by continuous subcutaneous infusion using an external pump in patients with type 1 diabetes. [2006.06]
Efficacy and safety of insulin glulisine in patients with type 1 diabetes. [2005.11]
Insulin glulisine, a new rapid-acting insulin analogue, displays a rapid time-action profile in obese non-diabetic subjects. [2005.09]
Pharmacokinetics, prandial glucose control, and safety of insulin glulisine in children and adolescents with type 1 diabetes. [2005.09]
A comparison of the steady-state pharmacokinetics and pharmacodynamics of a novel rapid-acting insulin analog, insulin glulisine, and regular human insulin in healthy volunteers using the euglycemic clamp technique. [2005.05]
Optimized Basal-bolus insulin regimens in type 1 diabetes: insulin glulisine versus regular human insulin in combination with Basal insulin glargine. [2005.01]
Insulin glulisine provides improved glycemic control in patients with type 2 diabetes. [2004.10]
Well-designed clinical trials possibly related to Apidra (Insulin Glulisine)
Dosing accuracy with a novel pen device (SoloSTAR) as performed by patients with diabetes in a clinical setting. [2008.08]
Other research related to Apidra (Insulin Glulisine)
Comparative effectiveness of basal-bolus versus premix analog insulin on glycemic
variability and patient-centered outcomes during insulin intensification in type
1 and type 2 diabetes: a randomized, controlled, crossover trial. [2012]
The pharmacokinetics and pharmacodynamics of rapid-acting insulin analogues and
their clinical consequences. [2012]
Optimizing Insulin Glargine Plus One Injection of Insulin Glulisine in Type 2 Diabetes in the ELEONOR Study: Similar effects of telecare and conventional self-monitoring of blood glucose on patient functional health status and treatment satisfaction. [2011.12]
Influence of preprandial vs. postprandial insulin glulisine on weight and glycaemic control in patients initiating basal-bolus regimen for type 2 diabetes: a multicenter, randomized, parallel, open-label study (NCT00135096). [2011.12]
Telecare Provides Comparable Efficacy to Conventional Self-Monitored Blood Glucose in Patients with Type 2 Diabetes Titrating One Injection of Insulin Glulisine-the ELEONOR Study. [2011.10.20]
Glycemic control with insulin glargine plus insulin glulisine versus premixed insulin analogues in real-world practices: a cost-effectiveness study with a randomized pragmatic trial design. [2011.07]
The effects of anti-insulin antibodies and cross-reactivity with human recombinant insulin analogues in the E170 insulin immunometric assay. [2011.01]
Optimizing insulin glargine plus one injection of insulin glulisine in type 2
diabetes in the ELEONOR study: similar effects of telecare and conventional
self-monitoring of blood glucose on patient functional health status and
treatment satisfaction. [2011]
A stepwise approach to insulin therapy in patients with type 2 diabetes mellitus
and basal insulin treatment failure. [2011]
Do different body colors and labels of insulin pens enhance a patient's ability
to correctly identify pens for injecting long-acting versus short-acting
insulins? [2011]
Comparable efficacy and safety of insulin glulisine and insulin lispro when given
as part of a Basal-bolus insulin regimen in a 26-week trial in pediatric patients
with type 1 diabetes. [2011]
Randomized study of basal-bolus insulin therapy in the inpatient management of
patients with type 2 diabetes undergoing general surgery (RABBIT 2 surgery). [2011]
Correct use of a new reusable insulin injection pen by patients with diabetes: a design validation study. [2010.09.01]
Insulin pump therapy in patients with type 2 diabetes safely improved glycemic control using a simple insulin dosing regimen. [2010.08]
Effective switch from premixed to basal-prandial insulin to achieve glycemic goals in type 2 diabetes. [2010.05]
Rapid-acting insulin analogues in Basal-bolus regimens in type 1 diabetes mellitus. [2010.05]
Insulin Glulisine Has a Faster Onset of Action Compared with Insulin Aspart in Healthy Volunteers. [2010.04.28]
Timing of meal insulin boluses to achieve optimal postprandial glycemic control in patients with type 1 diabetes. [2010.03]
Comparison between a basal-bolus and a premixed insulin regimen in individuals with type 2 diabetes-results of the GINGER study. [2010.02]
[Evaluation of a new disposable insulin pen and injection habits of diabetes patients in everyday clinical practice]. [2010.01.14]
Compatibility of insulin Lispro, Aspart, and Glulisine with the Solo MicroPump, a novel miniature insulin pump. [2010.01.01]
Bioequivalence between two human insulin analogs in Chinese population: Glulisine
and Lispro. [2010]
Insulin pump therapy in patients with type 2 diabetes safely improved glycemic
control using a simple insulin dosing regimen. [2010]
Usability, participant acceptance, and safety of a prefilled insulin injection device in a 3-month observational survey in everyday clinical practice in Australia. [2009.11.01]
Biphasic insulin aspart 30/70: pharmacokinetics and pharmacodynamics compared with once-daily biphasic human insulin and Basal-bolus therapy. [2009.08]
Insulin glulisine in the management of diabetes. [2009.07.07]
Preoperative hypoglycemia in a patient receiving insulin detemir. [2009.06]
Insulin glulisine: a review of its use in the management of diabetes mellitus. [2009.05.29]
Insulin glulisine: an evaluation of its pharmacodynamic properties and clinical application. [2009.04]
Insulin glulisine: aspects of basal/bolus therapy for optimized treatment of diabetes mellitus. [2009.03]
Insulin glulisine in the treatment of allergy to rapid acting insulin and its rapid acting analogs. [2009.01]
Vascular effects of rapid-acting insulin analogs in the diabetic patient: a review. [2009]
Introducing a simplified approach to insulin therapy in type 2 diabetes: a comparison of two single-dose regimens of insulin glulisine plus insulin glargine and oral antidiabetic drugs. [2008.12]
Usability of a pre-filled insulin injection device in a 3-month observational survey of everyday clinical practice in Australia. [2008.10]
Adjust to target in type 2 diabetes: comparison of a simple algorithm with carbohydrate counting for adjustment of mealtime insulin glulisine. [2008.07]
Options for the intensification of insulin therapy when basal insulin is not enough in type 2 diabetes mellitus. [2008.07]
Insulin glulisine, insulin lispro and regular human insulin show comparable end-organ metabolic effects: an exploratory study. [2008.06]
Adjust To Target In Type 2 Diabetes: Comparison Of A Simple Algorithm To Carbohydrate Counting For Adjustment Of Mealtime Insulin Glulisine. [2008.04.04]
Insulin, insulin analogues and diabetic retinopathy. [2008.02]
Clinical pharmacokinetics and pharmacodynamics of insulin glulisine. [2008]
New insulin analogues and routes of delivery: pharmacodynamic and clinical considerations. [2008]
A comparison of preprandial insulin glulisine versus insulin lispro in people with Type 2 diabetes over a 12-h period. [2007.12.26]
Comparison of in vitro stability for insulin aspart and insulin glulisine during simulated use in insulin pumps. [2007.12]
Patients with type 2 diabetes inadequately controlled on premixed insulin: effect of initiating insulin glargine plus oral antidiabetic agents on glycaemic control in daily practice. [2007.12]
Insulin glulisine: a faster onset of action compared with insulin lispro. [2007.09]
Insulin glulisine, insulin lispro and regular human insulin show comparable end-organ metabolic effects: an exploratory study. [2007.08.30]
A review of human and analogue insulin trials. [2007.07]
Evaluation of inhaled insulin therapy for diabetes mellitus. [2007.07]
Insulin glulisine: a faster onset of action compared with insulin lispro. [2007.06.26]
Insulin analogues in the treatment of diabetes in pregnancy. [2007.06]
Benefits of complementary therapy with insulin aspart versus human regular insulin in persons with type 2 diabetes mellitus. [2007.06]
Insulin glulisine imparts effective glycaemic control in patients with Type 2 diabetes. [2007.05]
Comparison of usability and patient preference for the new disposable insulin device Solostar versus Flexpen, lilly disposable pen, and a prototype pen: an open-label study. [2007.04]
Update in the pharmacologic treatment of diabetes: focus on insulin detemir, insulin glulisine, and inhaled dry powdered insulin. [2007.03]
Dose accuracy and injection force dynamics of a novel disposable insulin pen. [2007.03]
Insulin glulisine complementing basal insulins: a review of structure and activity. [2007.02]
Insulin analogues: new dimension of management of diabetes mellitus. [2007.01]
Insulin glulisine: efficacy and safety compared with other rapid-acting insulin analogues. [2007.01]
Combining insulins for optimal blood glucose control in type I and 2 diabetes: focus on insulin glulisine. [2007]
Insulin therapy in diabetes mellitus: how can the currently available injectable insulins be most prudently and efficaciously utilised? [2007]
[Short acting insulin analogues for treating diabetic patients with CSII (continuous subcutaneous insulin infusion)] [2006.11.19]
Insulin glulisine imparts effective glycaemic control in patients with Type 2 diabetes. [2006.11.17]
Novel insulin analogues and its mitogenic potential. [2006.11]
Advantage of premeal-injected insulin glulisine compared with regular human insulin in subjects with type 1 diabetes. [2006.08]
Narrative review: a rational approach to starting insulin therapy. [2006.07.18]
How well do rapid-acting insulins work in obese individuals? [2006.07]
Short acting insulin analogues versus regular human insulin in patients with diabetes mellitus. [2006.04.19]
Newer insulin analogues and inhaled insulin. [2006.03]
[Insulin analogues: searching for a physiological replacement] [2006.02]
Insulin glulisine. [2006]
[An update on multiple insulin injection therapy in type 1 and 2 diabetes] [2006]
Insulin glulisine. [2005.07]
Insulin therapy: current alternatives. [2005.05]
Insulin glulisine: a new rapid-acting insulin analogue for the treatment of diabetes. [2005.04]
Insulin analogues in the management of diabetes. [2004.07]
Insulin glulisine. Aventis Pharma. [2003.10]
|
